Frontlight ResearchEarly access
TerminatedPhase 2
Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer
Key facts
- Who runs it
- Huazhong University of Science and Technology
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 58 people enrolled
- Started
- 3 Apr 2020
- Ended
- 30 Nov 2023
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
- Albumin-bound Paclitaxel
- Record updated
- 4 November 2024
- Why it stopped
- slow recruitment forcing early suspension of screening and enrollment
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (22)Hide the full registry criteria
Who can take part
- Age of 18-70 years
- Second line treatment for cytological or histological diagnosis of recurrent or metastatic gastric and esophagogastric adenocarcinoma. Disease progression after adjuvant therapy within 6 months is eligible
- ECOG performance status of 0-2
- Estimated life expectancy of at least 3 months
- Bone marrow function: white blood cell count≥3.0×109 /L, absolute neutrophil count(ANC) ≥1.5×109 /L, platelet count(PLT) ≥90×109 /L, hemoglobin(HB) ≥90 g/L
- Left ventricular ejection fraction (LVEF) ≥ 50%
- Liver and kidney function: Creatinine(Cr)≤1.5 x upper limit of normal range(ULN); alanine glutamate transaminase (ALT) and glutamate transaminase (AST) ≤2.5 x upper limit of normal range (ULN), or ≤5 x upper limit of normal range (ULN)when with hepatic metastases,total bilirubin (TBIL)≤1.5 x upper limit of normal range (ULN), or≤2.5 x upper limit of normal range (ULN) when with Gilbert's syndrome
- Any acute, clinically significant treatment-related toxicity caused by previous treatment must have been reduced to less than or equal to grade 1, except hair loss
- Able and willing to comply with the study plans in this protocol and sign the informed consent
Who cannot take part
- uncontrollable infections or have received systematic antibiotic treatment within 72 hours before enrollment
- Have a second malignancy within 5 years prior to registration except for cured carcinoma in situ of cervix uteri, non-melanoma skin cancer
- Live vaccine was administered within 30 days before enrolment (injectable seasonal influenza vaccine is allowed as it is inactivated)
- Have participated in other clinical trials within 30 days prior to this study
- Allergic to the chemotherapy drugs or the materials in this study
- Suffering from mental or nervous system disorders and unable to cooperate
- Active autoimmune disease, history of autoimmune disease, use of corticosteroids or immunosuppressants, or use of hormone replacement therapy, such as thyroxine, insulin, etc
- Patients with other diseases not suitable for enrolment, such as active tuberculosis, hepatitis B (after treatment, hepatitis B virus titer HBV-DNA <500IU/ml, and liver function is normal, but cannot be combined with hepatitis C), hepatitis C, uncontrolled electrolyte disorders ,pericardial effusion, pleural effusion and abdominal effusion, etc
- History of organ transplantation
- Pregnant or nursing female patients. Men and women of reproductive age are unwilling to take reliable contraceptive measures during the study
- Any abnormal bone marrow hyperplasia or other abnormal hematopoietic function
- Patients with symptomatic brain metastases
- Patients that researcher consider cannot sign informed consent or complete the study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a Multi-center, Open-label, Randomized Controlled,phase 2 clinical trail of Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)Versus Albumin-bound Paclitaxel as Second-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma
The 2 groups in the trial
- Nab-P/PD-1Treatment being tested
Patients in this arm receive albumin-bound paclitaxel and SHR-1210 (PD-1 inhibitor) thepary.
Treatment: Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
- Nab-PExisting treatment, for comparison
Patients in this arm receive albumin-bound paclitaxel single-agent chemotherapy.
Treatment: Albumin-bound Paclitaxel
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-center, Open-label, Randomized Controlled Clinical Study of Nab-paclitaxel Plus SHR-1210(PD-1 Inhibitor)Versus Nab-paclitaxel As Second-line Treatment in Advanced or Recurrent Gastric and Esophagogastric Adenocarcinoma
- Publications
- Record updated
- 4 November 2024